Search 

EpicentRx is an immuno-oncology company whose focus is to identify and develop less toxic and more effective immunotherapy-based anti-cancer treatments that are active not only as single agents, but that also sensitize tumors to the cytotoxic effects of chemotherapy, radiation and immune checkpoint blockade. EpicentRx's lead program is among a portfolio of novel dinitroazetidine-based drugs that downregulate CD47 – SIRPα to alter the tumor microenvironment and optimize immune responses as well as normalize the tumor vasculature for better drug and oxygen delivery, and has been tested in several clinical trials including an ongoing Phase 3 study in SCLC. The company is also advancing multiple programs through its smart virus AdAPT platform, including three anti-SARS-CoV-2 vaccines, a TGF-beta "trap" starting Phase 1, and various personalized cancer vaccines that have shown to be effective in both chemotherapy and immune resistant tumors. For more information regarding EpicentRx, go to: http://www.epicentrx.com.

EpimAb's innovative FIT-Ig technology offers a game-changing approach to a broad variety of bi-specific antibodies. The technology provides access to stable bi-specifics by applying conventional molecular biology techniques. FIT-Ig molecules demonstrate properties similar to therapeutically active antibodies. They are actually manufactured like antibodies using standard processes at yields and purities similar to antibodies, e.g. EMB01, our first candidate was developed from cell line to IND submission date in 15 months, produced 3,5 g/l in a standard cell line and was easily purified with 70% recovery. Further candidates are manufactured with even higher yields.

EpimAb is developing a portfolio of bispecific antibodies for the treatment of different oncology indications. The first asset, EMB01, a first in class dual c-Met and EGFR inhibitor, is currently being investigated in a PhI/II study for treatment of solid tumors.

EMB02 (IND filing Q2/2020) and EMB04 are immune oncology biologics and EMB06 (IND filing Q4/2020) is a bispecific T-cell engager. In addition EMB08 (IND filing 2021) is a bispecific fusion protein.

EpimAb is committed to diversifying its portfolio of FIT-Igs in order to further validate the flexibility and robustness of the format and its platform. The broad applicability of this technology enables EpimAb to pursue two concurrent strategies for commercializing the technology:

•      Grant licenses to other pharmaceutical companies to combine two antibodies into a FIT-Ig themselves. Through this initiative EpimAb intends to catalyze the broad use of FIT-Igs for the benefit of scientists, the medical community and eventually patients; and

•      Create and develop proprietary FIT-Igs enabling EpimAb to grow and develop a discovery and development organization, generate FIT-Igs of great value to patients and medical experts and also improve its technological approach to bi-specific antibodies for the benefit of the scientific community.